
Ask a doctor about a prescription for IRBESARTAN TEVA 75 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Irbesartan Teva 75 mg film-coated tablets EFG
Irbesartan
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
Irbesartan belongs to a group of medicines called angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that constricts blood vessels, leading to an increase in blood pressure. Irbesartan Teva prevents angiotensin-II from binding to its receptors, relaxing blood vessels and lowering blood pressure. Irbesartan Teva slows down the progression of kidney damage in patients with high blood pressure and type 2 diabetes.
Irbesartan Teva is used in adult patients
Do not take Irbesartan Teva
Warnings and precautions
Consult your doctor before starting to take Irbesartan Teva and if any of the following apply to you:
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Irbesartan Teva”.
If you are pregnant, think you may be pregnant, or plan to become pregnant, inform your doctor. Irbesartan Teva is not recommended during the first trimester of pregnancy and must not be taken after the third month of pregnancy as it may cause serious harm to your baby (see section pregnancy).
Children and adolescents
This medicine should not be given to children under 18 years of age, as the safety and efficacy have not been fully established. If a child accidentally ingests several tablets, contact your doctor immediately.
Taking Irbesartan Teva with other medicines
Inform your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Your doctor may need to modify your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information under the headings “Do not take Irbesartan Teva” and “Warnings and precautions”).
You may need to have blood tests if you are taking:
If you are using a type of pain reliever known as non-steroidal anti-inflammatory medicines, the effect of irbesartan may be reduced.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will normally advise you to stop taking Irbesartan Teva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine to treat your high blood pressure. Irbesartan Teva should not be taken during the first trimester of pregnancy and must not be taken after the third month of pregnancy as it may cause serious harm to your baby.
Breastfeeding
Inform your doctor if you are breastfeeding or plan to start breastfeeding. It is not recommended to take Irbesartan Teva while breastfeeding, and your doctor may decide to give you a different treatment if you want to breastfeed, especially if you are breastfeeding a newborn or premature baby.
Driving and using machines
Irbesartan Teva is unlikely to affect your ability to drive or use machines. However, during treatment for high blood pressure, dizziness or fatigue may occasionally occur. If you experience these symptoms, consult your doctor before driving or using machines.
Irbesartan Teva contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per film-coated tablet; this is essentially “sodium-free”.
Always take this medicine exactly as your doctor has told you. If you are unsure, consult your doctor or pharmacist.
Method of administration
Irbesartan Teva is taken orally. The tablets should be swallowed with a sufficient amount of liquid (e.g., a glass of water). Irbesartan Teva can be taken with or without food. You should try to take your daily dose at the same time each day. It is important to continue taking Irbesartan Teva until your doctor tells you to stop.
The normal dose is 150 mg once daily. Depending on the response to blood pressure, this dose may be increased to 300 mg once daily.
In patients with high blood pressure and type 2 diabetes, the recommended maintenance dose for the treatment of kidney damage is 300 mg once daily.
Your doctor may advise a lower dose, especially when starting treatment, in certain patients, such as those on hemodialysisor over 75 years of age.
The maximum blood pressure-lowering effect should be achieved within 4-6 weeks after starting treatment.
If you take more Irbesartan Teva than you should
If you accidentally take too many tablets, contact your doctor immediately.
In case of overdose or accidental ingestion, contact the emergency department of the nearest hospital, your doctor, or call the Toxicology Information Service, telephone 915 620 420.
If you forget to take Irbesartan Teva
If you accidentally miss a dose, simply take your normal dose when it is due. Do not take a double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these side effects can be serious and may need medical attention.
As with similar medicines, rare cases of skin allergic reactions (rash, urticaria) and localized swelling in the face, lips, and/or tongue have been reported in patients treated with irbesartan. If you think you have had an allergic reaction or experience difficulty breathing, stop taking Irbesartan Teva and seek immediate medical attention.
List of side effects:
In patients with high blood pressure and type 2 diabetes with kidney damage, dizziness (especially when standing up), low blood pressure (especially when standing up), muscle or joint pain, and decreased levels of a protein present in red blood cells (hemoglobin).
Not known (cannot be estimated from the available data): feeling of spinning, headache, altered taste, ringing in the ears, muscle cramps, muscle and joint pain, reduced platelet count, abnormal liver function, high potassium levels in the blood, kidney function impairment, inflammation of small blood vessels, mainly in the skin area (a condition known as leucocytoclastic vasculitis), and severe allergic reactions (anaphylactic shock). Rare cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Irbesartan Teva
Appearance of the product and pack size
The film-coated tablets of Irbesartan Teva 75 mg are white to off-white and capsule-shaped. One side of the tablet is marked with the number “93”. The other side of the tablet is marked with the number “7464”.
Irbesartan Teva is available in pack sizes of 7, 14, 28, 30, 56, 60, 80, 84, 90, 98, and 100 film-coated tablets in non-perforated blisters; pack sizes of 50x1 and 56x1 film-coated tablets in unit-dose blisters and pack sizes of 28 film-coated tablets in non-perforated calendar blisters. Not all pack sizes may be marketed.
Not all pack sizes may be marketed.
Marketing authorisation holder:
Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands
Manufacturer:
Teva Operations Poland Sp.z.o.o
ul. Mogilska 80
31-546 Kraków
Poland
Teva Pharmaceutical Works Private Limited Company
Pallagi út 13
Debrecen H-4042
Hungary
TEVA UK Ltd
Brampton Road
Hampden Park
Eastbourne, East Sussex
BN22 9AG UK
United Kingdom
Pharmachemie B.V.
Swensweg 5
2031 GA Haarlem
Netherlands
You can get more information about this medicine by contacting the local representative of the marketing authorisation holder:
Belgium/Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG. Tel/Tél: +32 38207373 | Luxembourg/Luxemburg Teva Pharma Belgium S.A./A.G. Tél/Tel: +32 38207373 |
Bulgaria Teva Pharmaceuticals Bulgaria EOOD Tel: +359 24899582 | Hungary Teva Gyógyszergyár Zrt. Tel.: +36 12886400 |
Czech Republic Teva Pharmaceuticals CR, s.r.o. Tel: +420 251 007 111 | Malta Teva Pharmaceuticals Ireland Tel: +35351321740 |
Denmark Teva Denmark A/S Tlf: +45 44 98 55 11 | Netherlands Teva Nederland B.V. Tel: +31 (0) 800 0228400 |
Germany Teva GmbH Tel: +49731 402 08 | Norway Teva Norway AS Tlf: +47 66 77 55 90 |
Estonia Teva Eesti esindus UAB Sicor Biotech Eesti filiaal Tel: +372 6610801 | Austria ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43/1/97007-0 |
Greece Teva Ελλάς Α.Ε. Τηλ: +30 210 72 79 099 | Poland Teva Pharmaceuticals Polska Sp. z o.o. Tel.: +(48) 22 345 93 00 |
Spain Teva Pharma, S.L.U. Tél: +(34) 91 387 32 80 | Portugal Teva Pharma - Produtos Farmacêuticos Lda Tel: (351) 214 235 910 |
France Teva Santé Tél: +(33) 1 55 91 7800 | Romania Teva Pharmaceuticals S.R.L Tel: +4021 230 65 24 |
Croatia Pliva Hrvatska d.o.o Tel: +385 1 37 20 000 Ireland Teva Pharmaceuticals Ireland Tel: +353 (0)51 321 740 | Slovenia Pliva Ljubljana d.o.o. Tel: +386 1 58 90 390 |
Iceland ratiopharm Oy Finland Tel: +358 201805900 | Slovakia Teva Pharmaceuticals Slovakia s.r.o. Tel: +(421) 2 5726 7911 |
Italy Teva Italia S.r.l. Tel: +(39) 028917981 | Finland ratiopharm Oy Tel: +358 20 180 5900 |
Cyprus Teva Ελλάς Α.Ε. Τηλ: +30 210 72 79 099 | Sweden Teva Sweden AB Tel: +(46) 42 12 11 00 |
Latvia UAB Sicor Biotech filiale Latvija Tel: +371 67 323 666 | United Kingdom Teva UK Limited Tel: +44 1977628500 |
Lithuania UAB “Sicor Biotech” Tel: +370 5 266 02 03 |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/
The average price of IRBESARTAN TEVA 75 mg FILM-COATED TABLETS in December, 2025 is around 3.87 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for IRBESARTAN TEVA 75 mg FILM-COATED TABLETS – subject to medical assessment and local rules.